Liliana Nordbakk

Liliana Nordbakk is a Partner at NEVA SGR, the venture capital arm of the Intesa Sanpaolo Group, headquartered in Italy. She leads the firm’s life sciences investment division and is based in San Francisco, bringing a global perspective to early-stage biotech investing. Her focus areas include next-generation therapies, synthetic biology, precision medicine, and AI-enabled drug development.

Liliana’s career spans the intersection of information technology and biotechnology. She co-founded NorCom, a software company that she led through a successful IPO, and later co-founded Kamau Therapeutics, a clinical-stage gene correction company.

A long-standing member of the Silicon Valley investor community, she has been an active angel investor for over a decade and previously chaired the life sciences group at Band of Angels.

At NEVA, she champions transformative technologies that address the root causes of chronic diseases and aging-related decline. She has a particular interest in techbio platforms and frequently bridges European and American ecosystems to support globally scalable ventures.